TLN-372 for Advanced KRAS Mutant Solid Tumors
This study is testing a new drug called TLN-372 for people with advanced solid tumors that have a specific genetic change called a KRAS mutation. Researchers want to see how safe TLN-372 is, both on its own and when given with other anti-cancer drugs like cetuximab or pembrolizumab. They will also look at how well TLN-372 works to shrink tumors. To join, you must have measurable cancer, a KRAS mutation, and generally be in good health. You cannot have active brain metastases. The study will track side effects and tumor response for up to two years. The current status of this study is unclear.
- Study design
- This is an interventional study planning to enroll 270 participants. It is testing TLN-372 as a single agent and in combination with other drugs.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for safety and anti-tumor activity for up to 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
TLN-372 in Advanced KRAS Mutant Solid Tumors
At a glance
Conditions
Where it's being run
11 sites across 10 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of patients experiencing adverse events (AEs) that meet protocol-defined dose-limiting toxicity (DLT) criteria following administration of TLN-372Up to 2 years
- Incidence and severity of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs) leading to dose modification and discontinuation.Up to 2 years
- Anti-tumor activity of TLN-372 by evaluating the objective response rate (ORR) according to the RESIST v1.1Up to 2 years